Lb Pharmaceuticals (LBRX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $36.74, +0.14% vs the prior close of $36.69.
- Volume 724.74K shares, 2.0x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LBRX ends flat (+0.1%) to $36.74 on 2.0x normal volume. Closed at $36.74, +0.14% vs the prior close of $36.69. Day range $36.06–$37.37, opened at $36.62.
LBRX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LBRX ends flat (+0.1%) to $36.74 on 2.0x normal volume
- Closed at $36.74, +0.14% vs the prior close of $36.69. Day range $36.06–$37.37, opened at $36.62.
- Volume was 724.74K shares, 2.0x its 50-day average of 358.06K — unusually heavy trading.
- Price is -14.2% vs its 50-day average ($42.81) and +16.2% vs its 200-day average ($31.61).
- 52-week range $14.32–$50.16; today's close sits at 63% of that range, 26.8% below the 52-week high.
Oct 15, 2026 — LBRX jumps 7.9% to $36.69 on 2.8x normal volume
- Closed at $36.69, +7.91% vs the prior close of $34.00. Day range $34.50–$37.43, opened at $34.54.
- Volume was 976.60K shares, 2.8x its 50-day average of 344.88K — unusually heavy trading.
- Price is -14.8% vs its 50-day average ($43.04) and +16.3% vs its 200-day average ($31.54).
- 52-week range $14.32–$50.16; today's close sits at 62% of that range, 26.9% below the 52-week high.
Oct 14, 2026 — LBRX dips 2.3% to $34.00, a 1-month low, 3 down days in a row
- Closed at $34.00, -2.27% vs the prior close of $34.79. Day range $33.88–$35.51, opened at $34.10.
- Volume was 362.70K shares, 1.0x its 50-day average of 348.90K.
- Price is -21.3% vs its 50-day average ($43.21) and +8.1% vs its 200-day average ($31.46).
- 52-week range $14.32–$50.16; today's close sits at 55% of that range, 32.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — LBRX slides 3.2% to $34.79
- Closed at $34.79, -3.17% vs the prior close of $35.93. Day range $34.44–$36.10, opened at $36.10.
- Volume was 296.80K shares, 0.8x its 50-day average of 360.41K.
- Price is -19.9% vs its 50-day average ($43.43) and +10.8% vs its 200-day average ($31.40).
- 52-week range $14.32–$50.16; today's close sits at 57% of that range, 30.6% below the 52-week high.
Oct 12, 2026 — LBRX slides 3.5% to $35.93
- Closed at $35.93, -3.47% vs the prior close of $37.22. Day range $34.54–$37.43, opened at $37.26.
- Volume was 491.50K shares, 1.4x its 50-day average of 357.36K.
- Price is -17.6% vs its 50-day average ($43.59) and +14.7% vs its 200-day average ($31.34).
- 52-week range $14.32–$50.16; today's close sits at 60% of that range, 28.4% below the 52-week high.
Oct 9, 2026 — LBRX jumps 7.5% to $37.22 on 1.8x normal volume
- Closed at $37.22, +7.54% vs the prior close of $34.61. Day range $35.01–$38.50, opened at $35.01.
- Volume was 642.60K shares, 1.8x its 50-day average of 354.78K — unusually heavy trading.
- Price is -14.8% vs its 50-day average ($43.67) and +19.0% vs its 200-day average ($31.27).
- 52-week range $14.32–$50.16; today's close sits at 64% of that range, 25.8% below the 52-week high.
Oct 8, 2026 — LBRX rises 1.3% to $34.61
- Closed at $34.61, +1.32% vs the prior close of $34.16. Day range $33.13–$35.72, opened at $33.83.
- Volume was 440.70K shares, 1.2x its 50-day average of 360.16K.
- Price is -20.9% vs its 50-day average ($43.75) and +11.0% vs its 200-day average ($31.19).
- 52-week range $14.32–$50.16; today's close sits at 57% of that range, 31.0% below the 52-week high.
Oct 7, 2026 — LBRX ends flat (-0.3%) to $34.16, a 1-month low, 5 down days in a row
- Closed at $34.16, -0.29% vs the prior close of $34.26. Day range $34.00–$36.57, opened at $34.02.
- Volume was 385.00K shares, 1.1x its 50-day average of 358.27K.
- Price is -22.1% vs its 50-day average ($43.84) and +9.7% vs its 200-day average ($31.13).
- 52-week range $14.32–$50.16; today's close sits at 55% of that range, 31.9% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — LBRX dips 1.0% to $34.26, a 1-month low, 4 down days in a row
- Closed at $34.26, -1.04% vs the prior close of $34.62. Day range $33.73–$35.59, opened at $35.25.
- Volume was 432.80K shares, 1.2x its 50-day average of 353.97K.
- Price is -21.9% vs its 50-day average ($43.85) and +10.3% vs its 200-day average ($31.05).
- 52-week range $14.32–$50.16; today's close sits at 56% of that range, 31.7% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — LBRX slides 6.4% to $34.62, a 1-month low, 3 down days in a row
- Closed at $34.62, -6.41% vs the prior close of $36.99. Day range $34.47–$36.88, opened at $36.41.
- Volume was 494.50K shares, 1.4x its 50-day average of 350.76K.
- Price is -21.1% vs its 50-day average ($43.86) and +11.8% vs its 200-day average ($30.98).
- 52-week range $14.32–$50.16; today's close sits at 57% of that range, 31.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — LBRX dips 0.8% to $36.99, a 1-month low
- Closed at $36.99, -0.78% vs the prior close of $37.28. Day range $36.75–$38.81, opened at $37.72.
- Volume was 388.90K shares, 1.1x its 50-day average of 354.87K.
- Price is -15.7% vs its 50-day average ($43.87) and +19.7% vs its 200-day average ($30.90).
- 52-week range $14.32–$50.16; today's close sits at 63% of that range, 26.3% below the 52-week high.
LBRX latest news & SEC filings
Every SEC filing by or about LBRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 24, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 15, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 3, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$51.60M (prior year -$4.87M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.71 (prior year -$13.58) (loss narrowed vs Jun 30, 2025)
Things to know before you trade LBRX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.91% (largest 8.2%).
- Liquidity: about 472.48K shares (≈$17.36M) trade per day on average.
- 52-week position: $36.74 vs a range of $14.32–$50.16 (63% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 15, 2026; 8-K Sep 3, 2026; 10-Q Aug 11, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LBRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 36.62 | 37.37 | 36.06 | 36.74 | 724.74K |
| Oct 15, 2026 | 34.54 | 37.43 | 34.50 | 36.69 | 976.60K |
| Oct 14, 2026 | 34.10 | 35.51 | 33.88 | 34.00 | 362.70K |
| Oct 13, 2026 | 36.10 | 36.10 | 34.44 | 34.79 | 296.80K |
| Oct 12, 2026 | 37.26 | 37.43 | 34.54 | 35.93 | 491.50K |
| Oct 9, 2026 | 35.01 | 38.50 | 35.01 | 37.22 | 642.60K |
| Oct 8, 2026 | 33.83 | 35.72 | 33.13 | 34.61 | 440.70K |
| Oct 7, 2026 | 34.02 | 36.57 | 34.00 | 34.16 | 385.00K |
| Oct 6, 2026 | 35.25 | 35.59 | 33.73 | 34.26 | 432.80K |
| Oct 5, 2026 | 36.41 | 36.88 | 34.47 | 34.62 | 494.50K |
| Oct 2, 2026 | 37.72 | 38.81 | 36.75 | 36.99 | 388.90K |
| Oct 1, 2026 | 38.10 | 38.59 | 37.12 | 37.28 | 278.90K |
| Sep 30, 2026 | 37.61 | 39.23 | 37.34 | 38.38 | 437.20K |
| Sep 29, 2026 | 37.89 | 38.13 | 36.98 | 37.28 | 713.40K |
| Sep 28, 2026 | 37.24 | 38.17 | 36.57 | 37.89 | 534.60K |
| Sep 25, 2026 | 37.85 | 38.57 | 36.99 | 37.33 | 398.90K |
| Sep 24, 2026 | 39.13 | 39.39 | 37.56 | 37.80 | 413.50K |
| Sep 23, 2026 | 42.80 | 42.80 | 38.83 | 39.19 | 481.70K |
| Sep 22, 2026 | 43.40 | 43.40 | 41.21 | 42.69 | 244.40K |
| Sep 21, 2026 | 42.55 | 43.22 | 41.53 | 42.99 | 310.20K |
About Lb Pharmaceuticals
Lb Pharmaceuticals (LBRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1691082.
LBRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| J. Scott Garland | Director | Jun 5, 2026 |
| Rekha Hemrajani | Director | Jun 5, 2026 |
| William P Jr Kane | Director | Jun 5, 2026 |
| Robert A. Lenz | Director | Jun 5, 2026 |
| Rebecca Luse | Director | Jun 5, 2026 |
| Ran Nussbaum | Director | Jun 5, 2026 |
| Robert R Ruffolo | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Susan Gani Kozauer | Chief Medical Officer | Sep 24, 2026 |
| Joseph M Miller | Chief Financial Officer | Sep 14, 2026 |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | Dec 11, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
LBRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-25.20M | -3.13 | $-35.21M |
| Dec 31, 2024 | — | $-63.10M | -176.15 | $-53.05M |
Latest balance sheet: total assets $361.69M, total liabilities $29.34M, cash $283.11M (as of Jun 30, 2026).
LBRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $45.33 |
| May 12, 2026 | 8-K Item 2.02 (results) | $31.13 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $24.53 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $15.51 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LBRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.